Welcome to our dedicated page for Align Technology SEC filings (Ticker: ALGN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Align Technology filings document the regulatory record for a medical device company built around Invisalign clear aligners, iTero intraoral scanners, exocad CAD/CAM software and digital dentistry workflows. Its 8-K filings report operating and financial results, capital-structure actions, material events and governance changes, including bylaw amendments and executive compensation-related matters.
Proxy materials describe board structure, independence, risk oversight, shareholder voting items, executive compensation and governance policies. The filing record also captures shareholder meeting matters, stockholder rights provisions, common-stock disclosures and risk topics tied to Align's global clear-aligner, imaging systems and CAD/CAM services businesses.
Align Technology (ALGN) Q2 2025 10-Q highlights:
- Revenue: $1.01 bn, -1.6% YoY; Clear Aligner -3.3%, Systems & Services +5.6%.
- Margin: Gross margin 70.0% (70.2% LY); operating margin 16.1% vs 14.3% on lower legal costs.
- Earnings: Net income $124.6 m (+29%), diluted EPS $1.72 (+34%). Six-month EPS $2.98 (+11%).
- Cash & Liquidity: Cash & equivalents $901 m (-14% YTD); no debt; operating cash flow $181 m (-4%).
- Capital return: Completed $1 bn Jan-23 buyback; repurchased 1.34 m shares for $225 m in H1; new $1 bn Apr-25 program with $200 m OMR slated for H2.
- Share count: 72.5 m outstanding (-3.5% YoY).
- Legal/one-offs: Recorded $4.2 m additional accrual toward $31.75 m Section-1 antitrust settlement (prelim approval 5/28/25); VAT dispute with UK HMRC refunded ~$100 m but subject to appeal.
- Segment profit: Clear Aligner op-profit $267 m (-11%); Systems & Services $86 m (+21%).
- Balance sheet: Inventories $243.8 m (-4% YTD); goodwill now $491 m after Cubicure acquisition.
- Tax: Effective rate 28.2% vs 32.9%.
Key takeaways: Despite modest top-line contraction, disciplined expense control, share buybacks and favorable other income drove double-digit EPS growth. Cash burn and continuing legal/tax uncertainties temper outlook, but new $1 bn authorization reinforces management’s confidence.